New data from a Phase 3 clinical trial in China evaluating Novartis’ (NYSE:NVS) IL-17A inhibitor Cosentyx (secukinumab) in patients with moderate-to-severe plaque psoriasis showed a treatment...
New data from a Phase 3 clinical trial in China evaluating Novartis’ (NYSE:NVS) IL-17A inhibitor Cosentyx (secukinumab) in patients with moderate-to-severe plaque psoriasis showed a treatment...